Navidea (OTC:NAVB) has recently been embroiled in a trench war of litigation with its loan instrument Capital Royalty Group (CRG), which starting in the first part of 2016. CRG asserts a default on ...

Navidea had its first diagnostic product, Lymphoseek, approved in 2014. Sales growth has been steady for Lymphoseek, topping $10 million in 2015; however, litigation from a fund has threatened the ...

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma ...

Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of ...

Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development. The National Institute of Aging ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the ...

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a ...

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, ...